GO:0060168 positive regulation of adenosine receptor signaling pathway: Signaling Amplification, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060168 describes any process that activates or increases the frequency, rate or extent of the adenosine receptor signaling pathway, the cascade initiated when an adenosine receptor binds a physiological ligand.
• Positive regulation can occur through orthosteric agonists, positive allosteric modulators (PAMs), G-protein-derived peptides, and receptor-receptor crosstalk.
• Adenosine A1 receptor (ADORA1) positive allosteric modulation produces analgesia in rodent models, demonstrating that amplifying this pathway has direct therapeutic relevance.
• Adenosine A3 receptor (ADORA3) pharmacology is strongly species-dependent, which complicates translation of positive regulation findings between rodents and humans.
• Müller cell-microglia interplay in the retina involves adenosine receptor signaling components that can be positively regulated during inflammatory responses.
• CRISPR knockout, point-mutation, knock-in, and overexpression cell models are essential tools for dissecting which components causally amplify adenosine receptor signaling.
Description
The Gene Ontology term GO:0060168, positive regulation of adenosine receptor signaling pathway, is a biological process that encompasses any molecular event which activates or increases the frequency, rate or extent of signaling downstream of an adenosine receptor. Adenosine receptors are G protein-coupled receptors (GPCRs) that bind the endogenous purine nucleoside adenosine and transduce signals through heterotrimeric G proteins. Because adenosine is a ubiquitous metabolite whose extracellular concentration rises during stress, inflammation, and neuronal activity, the positive regulation of its receptor pathways is a central node in physiological adaptation and disease. Mechanistically, positive regulation can be achieved by orthosteric agonists that mimic adenosine, by positive allosteric modulators (PAMs) that enhance the efficacy or affinity of endogenous adenosine, or by intracellular effectors such as G-peptides that stabilize active receptor conformations. The A1 adenosine receptor (ADORA1) is a well-characterized example where PAMs produce analgesia by amplifying endogenous adenosine tone. Similarly, the A3 adenosine receptor (ADORA3) exhibits species-dependent pharmacology that directly affects how positive regulation is measured across model systems. For researchers, GO:0060168 matters because it defines the conceptual and experimental space for asking how adenosine receptor signals are amplified, which genes mediate this amplification, and how dysregulation contributes to diseases such as glaucoma, colitis, obesity-related metabolic dysfunction, and stroke. Understanding positive regulation at the receptor, G protein, and effector levels enables rational design of CRISPR models and pharmacological tools to test causality.
positive regulation of adenosine receptor signaling pathway At A Glance
| GO ID | GO:0060168 |
|---|---|
| GO term | positive regulation of adenosine receptor signaling pathway |
| Ontology | biological_process |
| Synonym | positive regulation of adenosine receptor signalling pathway |
| Definition | Any process that activates or increases the frequency, rate or extent of the adenosine receptor signaling pathway, the series of molecular signals generated as a consequence of an adenosine receptor binding to one of its physiological ligands. |
| Major function | Amplification of adenosine receptor signal transduction through orthosteric agonists, positive allosteric modulators, G-peptides, or downstream effector crosstalk. |
| Related receptors | ADORA1, ADORA2A, ADORA2B, ADORA3 |
| Related signaling | G protein-coupled receptor signaling, cAMP modulation, analgesia, inflammatory responses |
| Disease relevance | Glaucoma, colitis, obesity-related metabolic dysfunction, stroke |
What Is GO:0060168?
GO:0060168 is defined as any process that activates or increases the frequency, rate or extent of the adenosine receptor signaling pathway. The adenosine receptor pathway is the series of molecular signals generated as a consequence of an adenosine receptor binding to one of its physiological ligands. In practical terms, this term covers molecular events that enhance adenosine receptor signal transduction, including increased ligand availability, enhanced receptor activation, facilitated G protein coupling, or amplified downstream second messenger production.
Why Is positive regulation of adenosine receptor signaling pathway Important in Cell Biology?
Positive regulation of adenosine receptor signaling is important because adenosine is a fundamental homeostatic metabolite whose receptor pathways modulate pain, inflammation, metabolism, and neuronal survival. The ability to amplify these pathways pharmacologically or genetically provides a strategy to treat conditions where endogenous adenosine tone is insufficient, such as chronic pain, inflammatory bowel disease, and ischemic injury. Moreover, because adenosine receptor pharmacology is species-dependent, rigorous model systems are required to translate positive regulation findings into human therapies.
• Adenosine A1 receptor positive allosteric modulation produces analgesia, making GO:0060168 a direct target concept for pain therapeutics.
• Adenosine receptor signaling is involved in retinal inflammatory responses, and its positive regulation may exacerbate or resolve glaucoma-related neuroinflammation.
• Substance P attenuates colitis by suppressing inflammation and ferroptosis via cGAS-STING signaling, a pathway that intersects with adenosine receptor signaling networks.
• Adiponectin resistance in obesity involves adiponectin-leptin/insulin interactions that are modulated by adenosine receptor signaling components.
• Adenosine A3 receptor pharmacology is species-dependent, so positive regulation studies must account for model organism differences.
• G-peptides can allosterically modulate adenosine A1 and cannabinoid 1 receptor signaling, revealing conserved mechanisms of positive regulation.
• FGF17 synergistically targets neuronal survival and oligodendrogenesis to restore stroke deficits, a process where adenosine signaling may contribute to neuroprotection.
• CRISPR-based models enable causal testing of which genes positively regulate adenosine receptor signaling in disease-relevant cell types.
• Understanding positive regulation can guide development of PAMs with improved selectivity and reduced side effects compared to orthosteric agonists.
• Adenosine receptor signaling is a node for crosstalk with other GPCRs, expanding the therapeutic potential of positive regulation strategies.
What Happens During positive regulation of adenosine receptor signaling pathway?
Ligand availability and receptor occupancy
In simple terms: More adenosine around the receptor means more signal.
The first step in positive regulation is ensuring that adenosine or a synthetic agonist is available to bind the receptor. Endogenous adenosine levels rise during metabolic stress, inflammation, and neuronal activity, and any process that increases local adenosine concentration or delivery can positively regulate the pathway. Positive allosteric modulators can also enhance the apparent affinity of the receptor for adenosine without directly mimicking the ligand.
Receptor activation and conformational change
In simple terms: The receptor changes shape when it binds a ligand, turning the signal on.
Adenosine receptors are GPCRs that undergo conformational changes upon ligand binding. Positive regulation can occur when agonists or PAMs stabilize active receptor conformations, as demonstrated for the adenosine A1 receptor where PAMs enhance receptor-mediated analgesia. G-peptides can also allosterically modulate adenosine A1 receptor signaling by interacting with the receptor's intracellular face.
G protein coupling and effector activation
In simple terms: The activated receptor talks to G proteins, which then pass the message inside the cell.
Once activated, adenosine receptors couple to heterotrimeric G proteins, leading to modulation of effectors such as adenylyl cyclase and ion channels. Positive regulation of this step can involve enhanced G protein coupling efficiency or increased availability of downstream effectors. The specific G protein subtype and effector profile depend on the receptor subtype, with ADORA1, ADORA2A, ADORA2B, and ADORA3 exhibiting distinct coupling preferences.
Second messenger amplification and downstream signaling
In simple terms: The signal gets amplified inside the cell, affecting many processes.
Downstream of G protein activation, second messengers such as cAMP and calcium are modulated, leading to changes in kinase activity, gene expression, and cellular physiology. Positive regulation can amplify these second messenger responses, as seen in PTH-receptor signaling where Ca2+ allostery modulates pathway output. In the context of adenosine receptors, amplified signaling can influence inflammation, pain perception, and neuronal survival.
Crosstalk with other signaling pathways
In simple terms: Adenosine signals do not act alone; they talk to other pathways.
Positive regulation of adenosine receptor signaling often involves crosstalk with other GPCRs and signaling cascades. For example, G-peptides can modulate both adenosine A1 and cannabinoid 1 receptor signaling, indicating shared allosteric mechanisms. Additionally, adenosine receptor signaling intersects with inflammatory pathways such as cGAS-STING, which is modulated by substance P in colitis.
Key Genes Involved in GO:0060168 positive regulation of adenosine receptor signaling pathway
The following genes and proteins are central to the positive regulation of adenosine receptor signaling, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADORA1 | Adenosine A1 receptor; mediates analgesia and neuromodulation | Target for positive allosteric modulators in pain |
| ADORA2A | Adenosine A2A receptor; modulates inflammation and neuronal survival | Studied in neuroinflammation and stroke models |
| ADORA2B | Adenosine A2B receptor; involved in metabolic and inflammatory responses | Linked to obesity-related signaling |
| ADORA3 | Adenosine A3 receptor; species-dependent pharmacology | Model-dependent effects in inflammation |
| GNAS | G protein alpha s subunit; couples to ADORA2A/2B | Effector of positive regulation |
| GNAI1 | G protein alpha i1 subunit; couples to ADORA1/3 | Mediates inhibitory signaling |
| GNAI2 | G protein alpha i2 subunit; couples to ADORA1/3 | Mediates inhibitory signaling |
| GNAI3 | G protein alpha i3 subunit; couples to ADORA1/3 | Mediates inhibitory signaling |
| ADCY1 | Adenylyl cyclase 1; produces cAMP downstream of Gs | Effector of adenosine receptor signaling |
| ADCY5 | Adenylyl cyclase 5; produces cAMP downstream of Gs | Effector of adenosine receptor signaling |
| PRKACA | Protein kinase A catalytic subunit; mediates cAMP effects | Downstream effector |
| PRKACB | Protein kinase A catalytic subunit; mediates cAMP effects | Downstream effector |
| CGA | Glycoprotein hormones alpha subunit; crosstalk with GPCR signaling | Related to PTH-receptor signaling |
| PTH1R | Parathyroid hormone 1 receptor; GPCR with Ca2+ allostery | Model for GPCR positive regulation |
| CNR1 | Cannabinoid receptor 1; modulated by G-peptides | Crosstalk with adenosine A1 receptor |
| FGF17 | Fibroblast growth factor 17; neuroprotection in stroke | Potential upstream regulator |
| ADIPOR1 | Adiponectin receptor 1; metabolic signaling | Linked to obesity and adenosine crosstalk |
How Is positive regulation of adenosine receptor signaling pathway Regulated?
Positive regulation of adenosine receptor signaling is itself regulated at multiple levels. Receptor expression levels, ligand availability, and the presence of allosteric modulators determine the magnitude of the response. G-peptides can act as allosteric regulators of adenosine A1 and cannabinoid 1 receptors, providing a mechanism for intracellular modulation. Additionally, species-dependent differences in receptor pharmacology, particularly for ADORA3, mean that regulatory mechanisms identified in one organism may not translate directly to another. Crosstalk with other signaling pathways, such as cGAS-STING in inflammation, can also modulate the effective output of adenosine receptor signaling.
positive regulation of adenosine receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADORA1 | Pain and analgesia | Knock-in mouse with PAM-sensitive mutation |
| ADORA2A | Glaucoma and neuroinflammation | Retinal cell co-culture with microglia |
| ADORA3 | Inflammation (species-dependent) | Humanized knock-in mouse |
| ADIPOR1 | Obesity and metabolic dysfunction | Adipocyte-specific knockout |
| FGF17 | Stroke and neuronal survival | Overexpression in neuronal cells |
Adenosine receptor signaling in inflammatory and metabolic disease
Adenosine receptor signaling is deeply intertwined with inflammatory and metabolic pathways. In colitis, substance P attenuates inflammation and ferroptosis via the cGAS-STING signaling pathway, which intersects with adenosine receptor signaling networks. In obesity, adiponectin resistance involves complex interactions between adiponectin, leptin, and insulin, where adenosine receptor signaling components may modulate metabolic outcomes. These connections suggest that positive regulation of adenosine receptor signaling could be harnessed to resolve inflammation or improve metabolic function, but also that dysregulation may contribute to disease pathology.
Adenosine receptor signaling in retinal and neuronal disease
In experimental glaucoma, the interplay between Müller cells and microglia aggravates retinal inflammatory responses, a process in which adenosine receptor signaling components are involved. In stroke, FGF17 synergistically targets neuronal survival and oligodendrogenesis to restore deficits, and adenosine signaling may contribute to these neuroprotective mechanisms. Positive regulation of adenosine receptor signaling could therefore be protective or detrimental depending on context, highlighting the need for precise experimental models.
Adenosine receptor signaling in pain
The adenosine A1 receptor is a validated target for analgesia. Positive allosteric mechanisms of A1 receptor-mediated analgesia have been demonstrated, showing that amplifying endogenous adenosine signaling can produce pain relief without direct receptor activation. This makes GO:0060168 a key concept for developing pain therapeutics that enhance endogenous adenosine tone.
From positive regulation of adenosine receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ADORA1 abolish positive regulation of adenosine signaling? | ADORA1 knockout cell line |
| Does a point mutation in ADORA1 alter PAM sensitivity? | Point-mutation knock-in of ADORA1 |
| Can a tagged ADORA1 be used to track receptor trafficking? | Tagged knock-in of ADORA1 |
| Does overexpression of ADORA2A amplify downstream cAMP? | ADORA2A overexpression cell line |
| Which genes are required for adenosine-mediated analgesia? | CRISPR library screening in neuronal cells |
| Does ADORA3 species difference affect positive regulation? | Humanized ADORA3 knock-in mouse |
How to Study the positive regulation of adenosine receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Determine necessity of adenosine receptor genes |
| Point mutation | Specific amino acid function | Test allosteric sites in ADORA1 |
| Knock-in tagging | Receptor localization and trafficking | Live-cell imaging of ADORA1 |
| Overexpression | Gain of function | Amplify adenosine signaling |
| cAMP assay | Second messenger production | Measure positive regulation |
| Calcium imaging | Intracellular calcium flux | Assess downstream signaling |
| BRET/FRET sensors | Protein-protein interactions | Detect G protein coupling |
| RNA-seq | Transcriptional changes | Identify downstream targets |
CRISPR knockout and point-mutation models
CRISPR-Cas9 knockout of adenosine receptor genes (ADORA1, ADORA2A, ADORA2B, ADORA3) can determine which receptors are necessary for positive regulation. Point mutations can be introduced to test specific residues involved in allosteric modulation or G protein coupling, as demonstrated for the adenosine A1 receptor.
Knock-in and tagged knock-in models
Knock-in of fluorescent or epitope tags allows real-time tracking of receptor localization and trafficking. Tagged knock-in models of adenosine receptors can be used to visualize receptor activation and internalization in live cells, providing spatial and temporal resolution of positive regulation events.
Overexpression and rescue experiments
Overexpression of adenosine receptors or their downstream effectors can amplify signaling and reveal rate-limiting steps in positive regulation. Rescue experiments using wild-type versus mutant receptors can confirm the specificity of observed effects.
Pharmacological and biochemical assays
cAMP assays, calcium imaging, and radioligand binding are standard methods to measure adenosine receptor signaling. Positive allosteric modulation can be quantified by shifts in agonist dose-response curves, as shown for A1 receptor PAMs. G-peptide modulation can be assessed using GTPγS binding or BRET-based sensors.
How CRISPR Can Be Used to Study GO:0060168 positive regulation of adenosine receptor signaling pathway
Knockout
CRISPR knockout of adenosine receptor genes (ADORA1, ADORA2A, ADORA2B, ADORA3) is used to determine which receptors are required for positive regulation of signaling. For example, ADORA1 knockout abolishes A1 receptor-mediated analgesia, confirming its essential role. Knockout of downstream effectors such as GNAI subunits can reveal their contribution to pathway amplification.
Point Mutation
Point mutations can be introduced into adenosine receptors to dissect the molecular determinants of positive regulation. For instance, mutations in the allosteric site of ADORA1 can alter PAM sensitivity, providing mechanistic insight into how positive regulation is achieved. Similar approaches can be applied to ADORA3 to study species-dependent pharmacology.
Knock-in
Knock-in of reporter tags or humanized receptor sequences allows tracking of receptor expression and function in vivo. Humanized ADORA3 knock-in mice can be used to study positive regulation with human-specific pharmacology. Tagged ADORA1 knock-in enables visualization of receptor trafficking during analgesia.
Overexpression
Overexpression of adenosine receptors or their downstream effectors can amplify signaling and reveal rate-limiting steps. For example, overexpression of ADORA2A enhances cAMP responses to adenosine, providing a sensitized system to study positive regulation. Overexpression of G-peptides can allosterically modulate receptor activity.
How EDITGENE Supports positive regulation of adenosine receptor signaling pathway Research
Researchers studying positive regulation of adenosine receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in amplifying or dampening the pathway. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of adenosine receptor signaling pathway research.
Frequently Asked Questions About positive regulation of adenosine receptor signaling pathway
What is GO:0060168?
GO:0060168 is the Gene Ontology term for positive regulation of adenosine receptor signaling pathway, describing any process that activates or increases the frequency, rate or extent of signaling downstream of an adenosine receptor.
What genes are involved in positive regulation of adenosine receptor signaling?
Key genes include ADORA1, ADORA2A, ADORA2B, ADORA3, G protein subunits (GNAS, GNAI1/2/3), adenylyl cyclases (ADCY1, ADCY5), and protein kinase A subunits (PRKACA, PRKACB).
How does adenosine receptor signaling work?
Adenosine binds to G protein-coupled adenosine receptors, triggering conformational changes that activate heterotrimeric G proteins and downstream effectors such as adenylyl cyclase, leading to changes in cAMP and cellular responses.
What diseases are associated with adenosine receptor signaling?
Adenosine receptor signaling is linked to pain, glaucoma, colitis, obesity-related metabolic dysfunction, and stroke.
What are positive allosteric modulators of adenosine receptors?
Positive allosteric modulators (PAMs) are molecules that enhance the efficacy or affinity of adenosine at its receptor without directly activating the receptor, as shown for ADORA1-mediated analgesia.
Why is adenosine A3 receptor pharmacology species-dependent?
ADORA3 exhibits significant differences in ligand affinity and function between species, which affects how positive regulation findings translate from animal models to humans.
How can CRISPR be used to study adenosine receptor signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to test the causal role of specific genes in positive regulation of adenosine receptor signaling.
What is the role of G-peptides in adenosine receptor signaling?
G-peptides can allosterically modulate adenosine A1 and cannabinoid 1 receptor signaling, providing a mechanism for positive regulation at the intracellular level.
How does adenosine receptor signaling relate to inflammation?
Adenosine receptor signaling intersects with inflammatory pathways such as cGAS-STING, and positive regulation can modulate inflammatory responses in conditions like colitis and glaucoma.
What experimental models are best for studying positive regulation of adenosine receptor signaling?
Knockout, point-mutation, knock-in, and overexpression cell models, combined with cAMP assays and CRISPR screening, are widely used to dissect positive regulation mechanisms.
Conclusion
GO:0060168, positive regulation of adenosine receptor signaling pathway, is a critical biological process that governs how adenosine receptor signals are amplified. From positive allosteric modulation of ADORA1 for analgesia to species-dependent ADORA3 pharmacology, the mechanisms of positive regulation are diverse and disease-relevant. Understanding these mechanisms requires precise genetic models and pharmacological tools, which CRISPR-based approaches can provide. As research continues to uncover crosstalk between adenosine receptor signaling and pathways such as cGAS-STING and FGF17-mediated neuroprotection, the therapeutic potential of targeting positive regulation will expand. EDITGENE's suite of CRISPR services supports these investigations by enabling custom knockout, point-mutation, knock-in, and overexpression models tailored to adenosine receptor signaling research.
References
- 1. Lan J et al.. 2024. Neuropeptide substance P attenuates colitis by suppressing inflammation and ferroptosis via the cGAS-STING signaling pathway.. Int J Biol Sci 20(7):2507-2531 PMID: 38725846
- 2. Hu X et al.. 2021. Interplay between Müller cells and microglia aggravates retinal inflammatory response in experimental glaucoma.. J Neuroinflammation 18(1):303 PMID: 34952606
- 3. Draper-Joyce CJ et al.. 2021. Positive allosteric mechanisms of adenosine A(1) receptor-mediated analgesia.. Nature 597(7877):571-576 PMID: 34497422
- 4. Touma AM et al.. 2020. Allosteric modulation of adenosine A1 and cannabinoid 1 receptor signaling by G-peptides.. Pharmacol Res Perspect 8(6):e00673 PMID: 33124765
- 5. Engin A. 2024. Adiponectin Resistance in Obesity: Adiponectin Leptin/Insulin Interaction.. Adv Exp Med Biol 1460:431-462 PMID: 39287861
- 6. Gao ZG et al.. 2023. Species dependence of A(3) adenosine receptor pharmacology and function.. Purinergic Signal 19(3):523-550 PMID: 36538251
- 7. White AD et al.. 2019. Ca(2+) allostery in PTH-receptor signaling.. Proc Natl Acad Sci U S A 116(8):3294-3299 PMID: 30718391
- 8. Li Y et al.. 2026. FGF17 synergistically targets neuronal survival and oligodendrogenesis to restore stroke deficits.. Neurotherapeutics 23(4):e00954 PMID: 42398134
